Peng Enuo, Zeng Yayue, He Da, Tan Xiaojun, Xu Dabao, Zhao Xingping
Department of Gynecology, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Reproductive Center, Xiangtan Central Hospital, Xiangtan, Hunan, China.
Stem Cell Res Ther. 2025 May 1;16(1):219. doi: 10.1186/s13287-025-04359-6.
Intrauterine adhesions (IUAs) can easily cause female infertility or recurrent abortion, but there is still no effective treatment to improve the pregnancy and live birth rates in patients with IUAs. In recent years, great advances have been made in stem cell therapy; however, additional clarity is needed on the clinical efficacy of endometrial stem cells in the treatment of IUAs.
Fifteen patients with moderate-to-severe IUAs were included in the study at Xiangtan Central Hospital from 2018 to 2020. Patients were treated with endometrial stem cells and sodium hyaluronate gel by intrauterine perfusion in combination with estrogen and acetylsalicylic acid support therapy. Then, data on the pregnancy and live birth status was collected within two years after treatment. To explore the underlying mechanism, primary endometrial stem cells from healthy individuals and IUA patients, as well as fifth-generation endometrial stem cells from IUA patients, were further conducted with RNA sequencing to screen for differentially expressed genes, which were subsequently used for functional enrichment analysis.
After endometrial stem cell transplantation into the uterine cavity, the American Fertility Society scores of all patients decreased, and hysteroscopy revealed an improvement in the uterine condition and a reduction in adhesion symptoms. The total pregnancy rate of the 15 patients was 60.0% and the live birth rate was 53.3%. In addition, RNA sequencing analysis revealed that the cytokine - cytokine receptor interaction was associated with endometrial repair by endometrial stem cells.
Intrauterine infusion of autologous endometrial stem cells is highly effective for patients with moderate-to-severe IUA, and is a promising treatment strategy.
Chinese Clinical Trial Registry, CHICTR1800016769, Registered 22 June 2018- Retrospectively registered, https://www.chictr.org.cn/showproj.html?proj=27042 .
宫腔粘连(IUAs)易导致女性不孕或反复流产,但目前仍缺乏有效治疗方法来提高宫腔粘连患者的妊娠率和活产率。近年来,干细胞治疗取得了重大进展;然而,子宫内膜干细胞治疗宫腔粘连的临床疗效仍需进一步明确。
2018年至2020年,湘潭市中心医院纳入15例中重度宫腔粘连患者。患者接受子宫内膜干细胞和透明质酸钠凝胶宫腔灌注治疗,并联合雌激素和阿司匹林支持治疗。然后,收集治疗后两年内的妊娠和活产状态数据。为探究潜在机制,对健康个体和宫腔粘连患者的原代子宫内膜干细胞以及宫腔粘连患者的第五代子宫内膜干细胞进行RNA测序,以筛选差异表达基因,随后进行功能富集分析。
将子宫内膜干细胞移植到宫腔后,所有患者的美国生育协会评分均降低,宫腔镜检查显示子宫状况改善,粘连症状减轻。15例患者的总妊娠率为60.0%,活产率为53.3%。此外,RNA测序分析显示,细胞因子-细胞因子受体相互作用与子宫内膜干细胞介导的子宫内膜修复有关。
宫腔内输注自体子宫内膜干细胞对中重度宫腔粘连患者疗效显著,是一种有前景的治疗策略。
中国临床试验注册中心,CHICTR1800016769,2018年6月22日注册 - 回顾性注册,https://www.chictr.org.cn/showproj.html?proj=27042 。